Cullen/Frost Bankers’s Haemonetics HAE Stock Holding History

Cullen/Frost Bankers’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-27	Closed	-$2.01K	–	1382
2025 Q2	$2.01K	Sell	27 -42	-61%	-$2.78K	﹤0.01%	1178
2025 Q1	$4.38K	Buy	69 +14	+25%	+$952	﹤0.01%	1066
2024 Q4	$4.29K	Buy	55 +10	+22%	+$803	﹤0.01%	1029
2024 Q3	$3.62K	Buy	45 +8	+22%	+$646	﹤0.01%	1044
2024 Q2	$3.06K	Buy	+37	New	+$3.25K	﹤0.01%	1033
2022 Q2	–	Sell	-4	Closed	–	–	1120
2022 Q1	$0	Hold	4	–	–	﹤0.01%	1197
2021 Q4	$0	Buy	+4	New	+$244	﹤0.01%	1242

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cullen/Frost Bankers's HAE Position: Q3 2025 in Review

Cullen/Frost Bankers sold out of Haemonetics (HAE) in Q3 2025, closing a stake of 27 shares — an estimated $2.01K sold.

Cullen/Frost Bankers first reported a position in HAE in Q4 2021 and held it in 7 quarters. The position peaked at $4.38K in Q1 2025. 301 funds tracked by Wall St. Rank hold HAE as of Q3 2025.

Cullen/Frost Bankers reported no remaining Haemonetics position as of Q3 2025 after selling out during the quarter.
Cullen/Frost Bankers sold 27 Haemonetics shares in Q3 2025, an estimated $2.01K.
Cullen/Frost Bankers first reported a position in Haemonetics in Q4 2021 and held it in 7 quarters.
Cullen/Frost Bankers's Haemonetics position peaked at $4.38K in Q1 2025.
301 funds tracked by Wall St. Rank held Haemonetics as of Q3 2025.

Based on Cullen/Frost Bankers's 13F filing for Q3 2025, filed 31 Oct 2025.